Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Arch Biopartners Inc
ACHFF
Primary Symbol:
V.ARCH
Technology
Scientific & Technical Instruments
Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok...
). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:ARCH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 9:17pm
LSALT / Metablok Background
Inflammation Based Disease Inflammation is a localized physical condition that involves the activation of the immune system in response to infection, tissue injury, or autoimmunity. Inflammation is
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 9:10pm
dipeptidase-1 contribute to contrast-induced AKI
Renal immune surveillance and dipeptidase-1 contribute to contrast-induced acute kidney injury https://www.ncbi.nlm.nih.gov
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 9:07pm
LSALT Peptide (Metablok) team – lead scientists
LSALT Peptide Team
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 9:04pm
Dipeptidase-1 governs renal inflammation
Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury https://www.science.org
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 9:00pm
Dipeptidase-1 - Adhesion Receptor for Neutrophil Recruitor
Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver https://www.cell.com
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:56pm
Prime Minister Trudeau on Arch Biopartners
PM Trudeau 6.7 Mil Announcement
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:54pm
LSALT / Metablok Human Trials
clinicaltrials.gov
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:49pm
About DPEP-1 and Organ Inflammation
A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:44pm
(CIHR) Project Grant worth $1,109,250
To further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD). The CIHR grant entitled “A Multifaceted Function for Dipeptidase-1 in Kidney Injury” was
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:41pm
ARCH $4,000,000 funding from the National Research Council
The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:34pm
Active Pharma Executive - ARCH Strategic Advisor
Mr. Farris Smith started his career with AP Moller in 2001 and joined Novo Nordisk in 2003 as head of Finance and Human Resources for the Arabian Gulf countries and has since held finance and
...more
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 8:26pm
Treating Liver Inflammation
Treating Liver Inflammation
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 7:16am
Treating Kidney Inflammation
Treating Kidney Inflammation
(53)
•••
Riverfolk
X
View Profile
View Bullboard History
Post by
Riverfolk
on Apr 08, 2023 7:15am
Treating Lung Inflammation
Treating Lung Inflammation
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Xcyte Digital Corp. Releases "Xperience" Subscription Service
Drilling Approval Received for New Mexico Lithium Project
GameSquare Announces Formation of FaZe Media, Backed by $11M Investment